SCHEMBL994990

SCHEMBL994990

CC(C)(C)OC(=O)N1CCN[C@@H](CO)C1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.50
HPGD P15428 1/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RECQL P46063 1/20 0.40
MAPK1 P28482 1/20 0.40
EPHX1 P07099 1/20 0.38
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
REN P00797 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
PREP P48147 1/20 0.36
EPHX2 P34913 1/20 0.36
GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462710 1.00 NR1H2 (0.50) NR1H2HPGDMAPTMEN1ALDH1A1
SCHEMBL336866 1.00 NR1H2 (0.50) NR1H2HPGDMAPTMEN1ALDH1A1
Hydrochloric Acid SCHEMBL1162050 0.98 NR1H2 (0.49) NR1H2HPGDMAPTMEN1ALDH1A1
Hydrochloric Acid SCHEMBL1162048 0.98 NR1H2 (0.49) NR1H2HPGDMAPTMEN1ALDH1A1
Hydrochloric Acid SCHEMBL14150192 0.98 NR1H2 (0.49) NR1H2HPGDMAPTMEN1ALDH1A1
SCHEMBL28078177 0.92 NR1H2 (0.44) NR1H2HPGDMAPTMEN1ALDH1A1
SCHEMBL28078175 0.92 NR1H2 (0.44) NR1H2HPGDMAPTMEN1ALDH1A1
SCHEMBL17258176 0.91 NR1H2 (0.48) NR1H2HPGDMAPTMEN1ALDH1A1
SCHEMBL12836933 0.88 CA1 (0.45) NR1H2HPGDMAPTMEN1ALDH1A1
SCHEMBL14720039 0.88 CA1 (0.45) NR1H2HPGDMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813558-A Preparation method of (S) -2- (cyanomethyl) piperazine-1-carboxylic acid benzyl ester 南京优氟医药科技有限公司 2023-09-29 CN claimed
CN-116768804-A Preparation method of (S) -2- (piperazine-2-yl) acetonitrile hydrochloride 南京优氟医药科技有限公司 2023-09-19 CN claimed
CN-114349711-B Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine 四川依维欣医药科技有限公司 2023-08-15 CN claimed
CN-114349711-A Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine 四川恒康科技发展有限公司 2022-04-15 CN claimed
CN-109232613-A For treating and preventing the condensed heteroaryl dihydro-pyrimidin of hepatitis b virus infected new 6- 豪夫迈·罗氏有限公司 2019-01-18 CN claimed
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
CN-122055364-A PARP1 targeting compounds and uses thereof 成都赜灵生物医药科技股份有限公司 2026-05-15 CN disclosed
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 US disclosed
US-12612387-B2 RAS inhibitors and methods of using the same JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2026-04-28 US disclosed
US-20260078135-A1 POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 ENLIVEN INC (US) 2026-03-19 US disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 US disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 US disclosed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP disclosed
WO-2007075895-A2 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-07-05 WO disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 NR1H2 2132/4885HPGD 2348/4885MAPT 2034/4885
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS NR1H2 1937/4885HPGD 3057/4885MAPT 4771/4885
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels TRPV1, KCNJ2, KCNN3 NR1H2 1557/4885HPGD 633/4885MAPT 1856/4885
US-12612387-B2 RAS inhibitors and methods of using the same KRAS, NRAS, HRAS NR1H2 2854/4885HPGD 1988/4885MAPT 4857/4885
US-20260078135-A1 POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 ERBB2, BRCA1, ERBB3 NR1H2 138/4885HPGD 3986/4885MAPT 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.